Vaccine Therapy With or Without Donor Lymphocyte Infusion in Treating Patients With Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Multiple Myeloma Undergoing Donor Stem Cell Transplant

Study Overview
=================
Brief Summary
-----------------
RATIONALE: Vaccines made from the patient's cancer cells may help the body build an effective immune response to kill cancer cells. Giving vaccine therapy together with donor lymphocyte infusion after a stem cell transplant from the patient's brother or sister may kill any cancer cells that remain after transplant. PURPOSE: This clinical trial is studying the side effects, best dose, and how well vaccine therapy with or without donor lymphocyte infusion works in treating patients with acute myeloid leukemia, acute lymphoblastic leukemia, or multiple myeloma undergoing donor stem cell transplant.

Detailed Description
-----------------
OBJECTIVES: Determine time to relapse and overall survival of patients with high-risk acute myeloid leukemia, acute lymphoblastic leukemia, or multiple myeloma treated with autologous tumor cell vaccine with or without donor lymphocyte infusion after HLA-matched related sibling nonmyeloablative hematopoietic stem cell transplantation. Evaluate the safety and tolerability of this regimen in these patients. Determine the maximum tolerated dose of donor lymphocyte infusions in these patients. OUTLINE: Patients undergo collection of tumor cells for production of the cancer cell vaccine and then undergo HLA-matched related sibling nonmyeloablative hematopoietic stem cell transplantation (HSCT). Patients then receive cancer cell vaccine with or without donor lymphocyte infusion. The donor lymphocytes are obtained from the same relative who donated stem cells for the HSCT. PROJECTED ACCRUAL: A total of 30 patients will be accrued for this study.

Official Title
-----------------
Posttransplant Immunotherapy With Donor Lymphocyte Infusions and Autologous Tumor Vaccines After HLA-Matched Transplant

Conditions
-----------------
Leukemia, Multiple Myeloma and Plasma Cell Neoplasm

Intervention / Treatment
-----------------
* Biological: autologous tumor cell vaccine
* Biological: peripheral blood lymphocyte therapy


Participation Criteria
=================
Eligibility Criteria
-----------------
DISEASE CHARACTERISTICS: Confirmed diagnosis of 1 of the following: Acute myeloid leukemia (AML), meeting any of the following criteria: Relapsed disease AML arising from myelodysplastic syndromes Primary refractory disease De novo AML with high-risk features Acute lymphoblastic leukemia (ALL), meeting any of the following criteria: De novo ALL that is Philadelphia chromosome positive or with t(4,11) cytogenetic features Relapsed disease Multiple myeloma (in need of treatment) Planning to undergo HLA-matched related sibling nonmyeloablative hematopoietic stem cell transplantation PATIENT CHARACTERISTICS: Not specified PRIOR CONCURRENT THERAPY: See Disease Characteristics

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Biological: autologous tumor cell vaccine|nan|
|Biological: peripheral blood lymphocyte therapy|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Time to relapse |  |  | 
| Overall survival |  |  | 
| Safety and tolerability, in terms of incidence of graft-versus-host disease and local/systemic toxicities |  |  | 
| Maximum tolerated dose of donor lymphocytes |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
adult acute myeloid leukemia with 11q23 (MLL) abnormalities, adult acute myeloid leukemia with inv(16)(p13;q22), adult acute myeloid leukemia with t(15;17)(q22;q12), adult acute myeloid leukemia with t(16;16)(p13;q22), adult acute myeloid leukemia with t(8;21)(q22;q22), recurrent adult acute lymphoblastic leukemia, recurrent adult acute myeloid leukemia, secondary acute myeloid leukemia, stage III multiple myeloma, untreated adult acute lymphoblastic leukemia, untreated adult acute myeloid leukemia, stage I multiple myeloma, stage II multiple myeloma, refractory multiple myeloma